|
Author: Date Published: June-2010 Source: Bio-Medicine
According to a notice distributed by the agency, the US Food and Drug Administration (FDA) has approved United Therapeutics Corp.'s pulmonary arterial hypertension therapy Remodulin (treprostinil sodium).
|